A pretargeting system for tumor PET imaging and radioimmunotherapy

Frontiers in Pharmacology

Volumn 6, Issue MAR, 2015, Pages

  Kraeber Bodéré, Françoise ^a,b,c   Rousseau, Caroline ^b,c   Bodet Milin, Caroline ^a,c   Frampas, Eric ^a,c   Faivre Chauvet, Alain ^a,c   Rauscher, Aurore ^b,c   Sharkey, Robert M ^d   Goldenberg, David M ^d,e   Chatal, Jean François ^f   Barbet, Jacques ^c,f  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UMR INSERM U892 CNRS 6299   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d IMMUNOMEDICS INC   (United States)

^e CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^f GIP Arronax   (France)

Author keywords

Bispecific antibody; Immuno PET; Immunoscintigraphy; Pretargeting; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; COPPER 67; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; HAPTEN ANTIBODY; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; IODINE 131; RADIOISOTOPE; RHENIUM 186; RHENIUM 188; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 90; ZIRCONIUM 89;

ANTIBODY AFFINITY; BLOOD TOXICITY; BREAST CANCER; CANCER RADIOTHERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG MARKETING; HUMAN; ISOTOPE LABELING; LUNG CANCER; LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR; THYROID MEDULLARY CARCINOMA;

EID: 84926430481     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00054     Document Type: Review

References (56)

1. Barbet, J., Campion, L., Kraeber-Bodéré, F., and Chatal, J. F. (2005). GTE Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 90, 6077-6084. doi: 10.1210/jc.2005-0044.
2. Barbet, J., Peltier, P., Bardet, S., Vuillez, J. P., Bachelot, I., Denet, S., et al. (1998). Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J. Nucl. Med. 39, 1172-1178.
3. Boerman, O. C., Kranenborg, M. H., Oosterwijk, E., Griffiths, G. L., McBride, W. J., Oyen, W. J., et al. (1999). Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res. 59, 4400-4405.
4. Bos, E. S., Kuijpers, W. H., Meesters-Winters, M., Pham, D. T., de Haan, A. S., van Doornmalen, A. M., et al. (1994). In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer. Cancer Res. 54, 3479-3486.
5. Chang, C. H., Sharkey, R. M., Rossi, E. A., Karacay, H., McBride, W., Hansen, H. J., et al. (2002). Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol. Cancer Ther. 1, 553-563.
6. Chatal, J. F., Campion, L., Kraeber-Bodéré, F., Bardet, S., Vuillez, J. P., Charbonnel, B., et al. (2006). French Endocrine Tumor Group. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J. Clin. Oncol. 24, 1705-1711. doi: 10.1200/JCO.2005.04.4917.
7. Delbeke, D. (1999). Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J. Nucl. Med. 40, 591-603.
8. Frampas, E., Maurel, C., Remaud-Le Saëc, P., Mauxion, T., Faivre-Chauvet, A., Davodeau, F., et al. (2011). Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur. J. Nucl. Med. Mol. Imaging 38, 2153-2164. doi: 10.1007/s00259-011-1903-0.
9. Gautherot, E., Le Doussal, J. M., Bouhou, J., Manetti, C., Martin, M., Rouvier, E., et al. (1998). Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J. Nucl. Med. 39, 1937-1943.
10. Gautherot, E., Rouvier, E., Daniel, L., Loucif, E., Bouhou, J., Manetti, C., et al. (2000). Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J. Nucl. Med. 41, 480-487.
11. Gestin, J. F., Loussouarn, A., Bardiès, M., Gautherot, E., Gruaz-Guyon, A., Saï-Maurel, C., et al. (2001). Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. J. Nucl. Med. 42, 146-153.
12. Goldenberg, D. M. (1997). Perspectives on oncologic imaging with radiolabeled antibodies. Cancer 80, 2431-2435.
13. Goldenberg, D. M., Chang, C. H., Sharkey, R. M., Rossi, E. A., Karacay, H., McBride, W., et al. (2003). Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur. J. Nucl. Med. Mol. Imaging 30, 777-780. doi: 10.1007/s00259-002-1089-6.
14. Goldenberg, D. M., Preston, D. F., Primus, F. J., and Hansen, H. J. (1974). Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res. 34, 1-9.
15. Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., and Chatal, J. F. (2006). Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24, 823-834. doi: 10.1200/JCO.2005.03.8471.
16. Goodwin, D. A., Meares, C. F., McCall, M. J., McTigue, M., and Chaovapong, W. (1988). Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J. Nucl. Med. 29, 226-234.
17. Goodwin, D. A., Meares, C. F., McTigue, M., Chaovapong, W., Diamanti, C. I., Ransone, C. H., et al. (1992). Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J. Nucl. Med. 33, 2006-2013.
18. Goodwin, D. A., Meares, C. F., Watanabe, N., McTigue, M., Chaovapong, W., Ransone, C. M., et al. (1994). Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1, 4, 7, 10-tetraazacyclododecanetetraacetic acid (DOTA) in, BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy. Cancer Res. 54, 5937-5946.
19. Govindan, S. V., and Goldenberg, D. M. (2010). New antibody conjugates in cancer therapy. ScientificWorldJournal 10, 2070-2089. doi: 10.1100/tsw.2010.191.
20. Jain, M., Venkatraman, G., and Batra, S. K. (2007). Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin. Cancer Res. 13, 1374-1382. doi: 10.1158/1078-0432.CCR-06-2436.
21. Janevik-Ivanovska, E., Gautherot, E., Hillairet de Boisferon, M., Cohen, M., Milhaud, G., Tartar, A., et al. (1997). Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug. Chem. 8, 526-533. doi: 10.1021/bc970083h.
22. Karacay, H., Sharkey, R. M., Gold, D. V., Ragland, D. R., McBride, W. J., Rossi, E. A., et al. (2009). Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J. Nucl. Med. 50, 2008-2016. doi: 10.2967/jnumed.109.067686.
23. Kohler, G., and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497. doi: 10.1038/256495a0.
24. Kraeber-Bodéré, F., Bardet, S., Hoefnagel, C. A., Vieira, M. R., Vuillez, J. P., Murat, A., et al. (1999b). Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res. 5, 3190s-3198s.
25. Kraeber-Bodéré, F., Faibre-Chauvet, A., Saï-Maurel, C., Gautherot, E., Fiche, M., Campion, L., et al. (1999a). Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J. Nucl. Med. 40, 198-204.
26. Kraeber-Bodéré, F., Faivre-Chauvet, A., Ferrer, L., Vuillez, J. P., Brard, P. Y., Rousseau, C., et al. (2003). Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res. 9, 3973s-3981s.
27. Kraeber-Bodéré, F., Rousseau, C., Bodet-Milin, C., Ferrer, L., Faivre-Chauvet, A., Campion, L., et al. (2006). Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J. Nucl. Med. 47, 247-255.
28. Kranenborg, M. H., Boerman, O. C., Oosterwijk-Wakka, J. C., de Weijert, M. C., Corstens, F. H., and Oosterwijk, E. (1998). Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies. Int. J. Cancer 75, 74-80.
29. Le Doussal, J. M., Chetanneau, A., Gruaz-Guyon, A., Martin, M., Gautherot, E., Lehur, P. A., et al. (1993). Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J. Nucl. Med. 34, 1662-1671.
30. Le Doussal, J. M., Gruaz-Guyon, A., Martin, M., Gautherot, E., Delaage, M., and Barbet, J. (1990). Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res. 50, 3445-3452. Erratum in: Cancer Res. 1990, 50, 6115.
31. Le Doussal, J. M., Martin, M., Gautherot, E., Delaage, M., and Barbet, J. (1989). In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J. Nucl. Med. 30, 1358-1366.
32. Lollo, C., Halpern, S., Bartholomew, R., David, G., and Hagan, P. (1994). Non-covalent antibody-mediated drug delivery. Nucl. Med. Commun. 15, 483-491. doi: 10.1097/00006231-199406000-00014.
33. Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., et al. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90, 2188-2195.
34. McBride, W. J., Sharkey, R. M., Karacay, H., D'Souza, C. A., Rossi, E. A., Laverman, P., et al. (2009). A novel method of 18F radiolabeling for PET. J. Nucl. Med. 50, 991-998. doi: 10.2967/jnumed.108.060418.
35. McBride, W. J., Zanzonico, P., Sharkey, R. M., Norén, C., Karacay, H., Rossi, E. A., et al. (2006). Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J. Nucl. Med. 47, 1678-1688.
36. Mirallié, E., Vuillez, J. P., Bardet, S., Frampas, E., Dupas, B., Ferrer, L., et al. (2005). High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J. Clin. Endocrinol. Metab. 90, 779-788. doi: 10.1210/jc.2004-1500.
37. Paganelli, G., and Chinol, M. (2003). Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur. J. Nucl. Med. Mol. Imaging 30, 773-776. doi: 10.1007/s00259-002-1090-0.
38. Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., et al. (1991). Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 51, 5960-5966.
39. Peltier, P., Curtet, C., Chatal, J. F., Le Doussal, J. M., Daniel, G., Aillet, G., et al. (1993). Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J. Nucl. Med. 34, 1267-1273.
40. Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., McBride, W. J., Sharkey, R. M., and Chang, C. H. (2006). Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc. Natl. Acad. Sci. U.S.A. 103, 6841-6846. doi: 10.1073/pnas.0600982103.
41. Salaun, P. Y., Campion, L., Ansquer, C., Frampas, E., Mathieu, C., Robin, P., et al. (2014). 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 41, 1501-1510. doi: 10.1007/s00259-014-2772-0.
42. Salaun, P. Y., Campion, L., Bournaud, C., Faivre-Chauvet, A., Vuillez, J. P., Taieb, D., et al. (2012). Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J. Nucl. Med. 53, 1185-1192. doi: 10.2967/jnumed.111.101865.
43. Schoffelen, R., Boerman, O. C., Goldenberg, D. M., Sharkey, R. M., van Herpen, C. M., Franssen, G. M., et al. (2013). Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br. J. Cancer. 109, 934-942. doi: 10.1038/bjc.2013.376.
44. Schoffelen, R., Sharkey, R. M., Goldenberg, D. M., Franssen, G., McBride, W. J., Rossi, E. A., et al. (2010a). Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga-and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol. Cancer Ther. 9, 1019-1027. doi: 10.1158/1535-7163.MCT-09-0862.
45. Schoffelen, R., van der Graaf, W. T., Franssen, G., Sharkey, R. M., Goldenberg, D. M., McBride, W. J., et al. (2010b). Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J. Nucl. Med. 51, 1780-1787. doi: 10.2967/jnumed.110.079376.
46. Schoffelen, R., Woliner-van der Weg, W., Visser, E. P., Goldenberg, D. M., Sharkey, R. M., McBride, W. J., et al. (2014). Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. Eur. J. Nucl. Med. Mol. Imaging 41, 1593-1602. doi: 10.1007/s00259-014-2742-6.
47. Schoffelen, R., van der Graaf, W. T., Sharkey, R. M., Franssen, G. M., McBride, W. J., Chang, C. H., et al. (2012). Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer. J. Nucl. Med. 53, 1926-1932. doi: 10.2967/jnumed.112.106278.
48. Schuhmacher, J., Kaul, S., Klivényi, G., Junkermann, H., Magener, A., Henze, M., et al. (2001). Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res. 61, 3712-3717.
49. Sharkey, R. M., McBride, W. J., Karacay, H., Chang, K., Griffiths, G. L., Hansen, H. J., et al. (2003). A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 63, 354-363.
50. Sharkey, R. M., van Rij, C. M., Karacay, H., Rossi, E. A., Frielink, C., Regino, C., et al. (2012). A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers. J. Nucl. Med. 53, 1625-1632. doi: 10.2967/jnumed.112.104364.
51. Stickney, D. R., Anderson, L. D., Slater, J. B., Ahlem, C. N., Kirk, G. A., Schweighardt, S. A., et al. (1991). Bifunctional antibody: a binary radio-pharmaceutical delivery system for imaging colo-rectal carcinoma. Cancer Res. 51, 6650-6655.
52. van Dongen, G. A., and Vosjan, M. J. (2010). Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother. Radiopharm. 25, 375-385. doi: 10.1089/cbr.2010.0812.
53. van Rij, C. M., Lütje, S., Frielink, C., Sharkey, R. M., Goldenberg, D. M., Franssen, G. M., et al. (2013). Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur. J. Nucl. Med. Mol. Imaging 40, 1377-1383. doi: 10.1007/s00259-013-2434-7.
54. Vugts, D. J., Visser, G. W., and van Dongen, G. A. (2013). 89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals. Curr. Top. Med. Chem. 13, 446-457. doi: 10.2174/1568026611313040005.
55. Vuillez, J. P., Moro, D., Brichon, P. Y., Rouvier, E., Brambilla, E., Barbet, J., et al. (1997). Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J. Nucl. Med. 38, 507-511.
56. Wilder, R. B., DeNardo, G. L., and DeNardo, S. J. (1996). Radioimmunotherapy: recent results and future directions. J. Clin. Oncol. 14, 1383-1400.